.Pharmacolibrary.Drugs.ATC.D.D11AH01

Information

Tacrolimus is a calcineurin inhibitor with potent immunosuppressive properties. It is primarily used to prevent organ transplant rejection and to treat autoimmune diseases such as atopic dermatitis. It is approved for clinical use worldwide.

Pharmacokinetics

Pharmacokinetic model for adult healthy volunteers and transplant recipients; both sexes. Oral administration; data primarily referenced from studies on liver and kidney transplant patients.

References

1. Martial, LC, et al., & Moes, DJAR (2021). Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. British journal of clinical pharmacology 87(11) 4262–4272. DOI:10.1111/bcp.14842 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33786892

2. Teng, F, et al., & Wei, H (2022). Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients. Biopharmaceutics & drug disposition 43(2) 76–85. DOI:10.1002/bdd.2311 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35220592

3. Kamp, J, et al., & Moes, DJAR (2023). Meltdose Tacrolimus Population Pharmacokinetics and Limited Sampling Strategy Evaluation in Elderly Kidney Transplant Recipients. Pharmaceutics 16(1) –. DOI:10.3390/pharmaceutics16010017 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38276495

Revisions

• 06/2025 initial generated model